Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen

NEXT STORY
OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
PREV STORY
Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mesoblast Receives Ethics Approval to Treat COVID-19 Patients in Australia

author_avatar
NASDAQ Market News

Samumed Announces Results of Phase 2 Trial of SM04690 Demonstrating Evidence of Cartilage Regeneration in Patients with Knee Osteoarthritis

- Data support potential of SM04690 as a disease modifying drug for knee osteoarthritis ...

author_avatar
NASDAQ Market News

Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

author_avatar
NASDAQ Market News